Fundraising Fox
Xilio Therapeutics
NASDAQ: XLOWaltham, US · Founded 2020 · Delaware corporation · 96 employees on LinkedIn · 16 known investors
Find your way into Xilio Therapeutics
Sign up to see every warm intro you have to Xilio Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Xilio Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Founders & leadership
Xilio Therapeutics was founded in 2020 by René Russo.
Board
Investors · 16
How we know: Bain Capital Life Sciences's portfolio page · board seat on SEC Form D · funding news · Not right? Tell us
How we know: F-Prime Capital's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: M Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: MRL Ventures Fund's portfolio page · the S-1 prospectus · funding news · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: SV Health Investors's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: baincapital.com · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$145.2M disclosed across 2 of 5 rounds · 1900–2026
▶$95MraisedFeb 2021 · 17 investors · BiotechnologyRule 506(b)
- Rachel HumphreyDirector
- Andrew HackDirector
- David GrayzelDirector
- Daniel LynchDirector
- Michael RossDirector
- Joseph FarmerExecutive Officer
- Rene RussoExecutive Officer, Director
- Timothy ClacksonExecutive Officer
- Paul ClancyDirector
- Daniel CurranDirector
- David GardnerDirector
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50.2MraisedJan 2021 · 16 investors · BiotechnologyRule 506(b)
- Paul ClancyDirector
- Daniel CurranDirector
- Peter DudekDirector
- David GrayzelDirector
- Nancy HongDirector
- Rachel HumphreyDirector
- Daniel LynchDirector
- Michael RossDirector
- Robert WeisskoffDirector
- Joseph FarmerExecutive Officer
- Rene RussoExecutive Officer, Director
- Timothy ClacksonExecutive Officer
- Offering amount
- $50.2M
- Amount sold
- $50.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Xilio Therapeutics went on to found or lead other companies.
Related companies · 5
Companies working in the same space as Xilio Therapeutics.
Frequently asked questions
- What does Xilio Therapeutics do?
- Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
- Who founded Xilio Therapeutics?
- Xilio Therapeutics was founded by René Russo in 2020.
- Who are Xilio Therapeutics's investors?
- Xilio Therapeutics's investors include Bain Capital Life Sciences, Bay City Capital, F-Prime Capital, M Ventures, MRL Ventures Fund, RA Capital, RiverVest Venture Partners, Solasta Ventures and 8 more.
- How much funding has Xilio Therapeutics raised?
- Xilio Therapeutics has disclosed $145.2M raised across 2 of its 5 known rounds.
- Where is Xilio Therapeutics headquartered?
- Xilio Therapeutics is headquartered in Waltham, US.